Evaluating the thresholds of abnormal second trimester multiple marker screening tests associated with intra-uterine growth restriction

American Journal of Perinatology

Volumn 23, Issue 6, 2006, Pages 363-367

  Odibo, Anthony O ^a,b   Sehdev, Harish M ^c   Stamilio, David M ^b   Macones, George A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Abnormal biochemical markers; Growth restriction; Prediction

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; ESTRIOL;

ADULT; ARTICLE; CASE CONTROL STUDY; FEMALE; FETUS; FETUS ECHOGRAPHY; FETUS MALFORMATION; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY;

ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN; DATABASES, FACTUAL; ESTRIOL; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 33747623988     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947724     Document Type: Article

References (19)

1. Milunsky A, Nebiolo L. Maternal serum triple analyte screening and adverse pregnancy outcome. Fetal Diagn Ther 1996;11:249-253
2. Schleifer RA, Bradley LA, Richards DS, Ponting NR. Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening. Am J Obstet Gynecol 1995;173:1152-1156
3. Benn PA, Horne D, Briganti S, Rodis JF, Clive JM. Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein. Obstet Gynecol 1996; 87:217-222
4. Chandra S, Scott H, Dodds L, Blight C, Van Den Hof M. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 2003;189:775-781
5. Simpson JL, Palomaki GE, Mercer B, et al. Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. Am J Obstet Gynecol 1995;173:1742-1748
6. Burton BK. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 1988;72:709-713
7. Waller DK, Lustig LS, Cunningham GC, Golbus MS, Hook EB. Second trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death. N Engl J Med 1991;325:6-10
8. Onderoglu LS, Kabukcu A. Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome. Int J Gynaecol Obstet 1997;56:245-249
9. Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M. The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 1992;80:83-86
10. Berkeley AS, Killackey MA, Cederqvist LL. Elevated maternal serum alpha-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier. Am J Obstet Gynecol 1983;146:859-861
11. Bartha JL, Romero-Carmona R, Escobar-Llompart M, Paloma-Castro O, Comino-Delgado R. Human chorionic gonadotropin and vascular endothelial growth factor in normal and complicated pregnancies. Obstet Gynecol 2003;102:995-999
12. Kowalczyk TD, Cabaniss ML, Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998;91:396-400
13. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163-168
14. Ilagan JG, Stamilio DM, Ural SH, Macones GA, Odibo AO. Abnormal multiple marker screens are associated with adverse perinatal outcomes in cases of intrauterine growth restriction. Am J Obstet Gynecol 2004;191:1465-1469
15. Yaron Y, Cherry M, Kramer RL, et al. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999;181:968-974
16. Dugoff L, Hobbins JC, Malone FD, et al. FASTER Trial Research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005;106:260-267
17. Lieppman RE, Williams MA, Cheng EY, et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am J Obstet Gynecol 1993;168:1852-1856
18. Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free beta hCG, PAPP-A and inhibin-A. Prenat Diagn 2003;23:990-996
19. Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004;191:1452-1458